StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Investment analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday.

Can-Fite BioPharma Trading Down 2.4 %

CANF stock opened at $1.20 on Wednesday. The firm has a 50-day moving average of $1.55 and a two-hundred day moving average of $1.77. The firm has a market capitalization of $4.25 million, a PE ratio of -0.67 and a beta of 1.37. Can-Fite BioPharma has a one year low of $1.18 and a one year high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.